Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s396, 2024. DOI: 10.25251/skin.8.supp.396. Disponível em: https://skin.dermsquared.com/skin/article/view/2671. Acesso em: 18 apr. 2025.